SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
Anna Murasheva, Oksana Fuks, Natalya Timkina, Arina Mikhailova, Timur Vlasov, Konstantin Samochernykh, Tatiana Karonova · 2024
Read SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke by Anna Murasheva, Oksana Fuks, Natalya Timkina, Arina Mikhailova, Timur Vlasov, Konstantin Samochernykh, Tatiana Karonova (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11673681.txt.
Description
Anna Murasheva and six co-authors test in 2024 whether two classes of diabetes drugs can limit brain damage in experimental stroke. The drugs, SGLT-2 inhibitors and GLP-1 receptor agonists, are known to protect the heart and kidneys, but whether they shield the brain, and how, is unsettled.
The team gave the drugs to rats with and without diabetes before inducing strokes, using two SGLT-2 drugs of differing selectivity and one GLP-1 drug. They measured the size of the brain damage and the animals' neurological state afterward. The study digs into how these widely used drugs might help or fail the injured brain.
Catalog record
| CREATOR | Anna Murasheva, Oksana Fuks, Natalya Timkina, Arina Mikhailova, Timur Vlasov, Konstantin Samochernykh, Tatiana Karonova |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |